Cara Therapeutics Inc
NASDAQ:TVRD
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Cara Therapeutics Inc
NASDAQ:CARA
|
83.4m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
948.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
282.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
211.8B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.1B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
223B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.4B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
98.2B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Cara Therapeutics Inc
Glance View
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Cara Therapeutics Inc is -993%, which is below its 3-year median of -692.6%.
Over the last 3 years, Cara Therapeutics Inc’s Net Margin has decreased from -384.3% to -993%. During this period, it reached a low of -1 099.8% on Sep 30, 2024 and a high of -135.6% on Jun 30, 2022.
